Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 : A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19
Eligible patients with SARS-CoV-2 infection confirmed by a positive virus test and who are hospitalised due to COVID-19 and require oxygen therapy, will be randomised in a 1:1 ratio to receive SNG001 two syringes or placebo two syringes. SNG001 or placebo will be administered via the Ultra nebuliser. Patients will receive a dose of SNG001 or placebo once a day for 14 days and will be followed up for up to 90 days after the first dose of study medication. Study data will be collected from patients daily, as per the study schedule..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ClinicalTrials.gov - (2023) vom: 27. März Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: February 1, 2021, Last downloaded: ClinicalTrials.gov processed this data on April 05, 2023, Last updated: April 05, 2023 |
---|
Study ID: |
NCT04732949 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003656535 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003656535 | ||
003 | DE-627 | ||
005 | 20230425212011.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003656535 | ||
035 | |a (UBBS_Klinische_Studien)NCT04732949 | ||
035 | |a (UBBS_Klinische_Studien)SG018 | ||
035 | |a (UBBS_Klinische_Studien)2020-004743-83 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 |b A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19 |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: February 1, 2021, Last downloaded: ClinicalTrials.gov processed this data on April 05, 2023, Last updated: April 05, 2023 | ||
520 | |a Eligible patients with SARS-CoV-2 infection confirmed by a positive virus test and who are hospitalised due to COVID-19 and require oxygen therapy, will be randomised in a 1:1 ratio to receive SNG001 two syringes or placebo two syringes. SNG001 or placebo will be administered via the Ultra nebuliser. Patients will receive a dose of SNG001 or placebo once a day for 14 days and will be followed up for up to 90 days after the first dose of study medication. Study data will be collected from patients daily, as per the study schedule. | ||
650 | 2 | |a COVID-19 | |
650 | 2 | |a Coronavirus Infections | |
650 | 2 | |a Severe Acute Respiratory Syndrome | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Completed | |
650 | 4 | |a Phase: Phase 3 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 27. März |
773 | 1 | 8 | |g year:2023 |g day:27 |g month:03 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04732949 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2023 |b 27 |c 03 |